Nacubactam - Roche

Drug Profile

Nacubactam - Roche

Alternative Names: FPI-1459; OP-0595; RG 6080; RO 7079901

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fedora Pharmaceuticals
  • Developer Meiji Seika Pharma; Roche
  • Class Antibacterials; Azabicyclo compounds
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 24 Apr 2018 Safety and pharmacokinetics data from phase I trial in healthy volunteers presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in murine septicaemia model presented at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID-2018)
  • 15 Dec 2017 Roche completes a phase I trial in Bacterial infections (Combination therapy) in USA, Serbia, Poland, Latvia, Hungary (IV) (NCT03174795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top